Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing --


-- Data Supports the Study of RLYB116 as a Differentiated...

Related Keywords

New Haven ,Connecticut ,United States ,Eric Watsky ,Linkedin ,Term Development ,Rallybio Corporation Nasdaq ,Exchange Commission ,Program Lead For Rallybio ,Twitter ,Rallybio Corporation ,Term Development Plans ,Stephen Uden ,Chief Executive Officer ,Technology Incubation Program ,Quarterly Report ,Markets ,